$73.64
+0.97 (+1.33%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NKTR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
39 interventional · 23 with posted results
Held by 12 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, PRIMECAP MANAGEMENT CO/CA/, CITADEL ADVISORS LLC, +7 more) · FINRA short interest 8.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNCT07711418US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Rezpegaldesleukin, Placebo | Moderate-to-Severe Atopic Dermatitis | 510 | Jun 2028 | ≤ 681 d | 2026-07-17 |
| A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNCT07690371US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Rezpegaldesleukin, Placebo | Moderate-to-Severe Atopic Dermatitis | 510 | May 2028 | ≤ 651 d | 2026-08-04 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)NCT06340360Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Rezpegaldesleukin, Placebo | Alopecia Areata | 94 | 2025-11-26actual | — | 2026-07-10 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNCT06136741Mean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Rezpegaldesleukin, Placebo | Moderate to Severe Atopic Dermatitis | 396 | 2025-05-06actual | — | 2026-08-03 |
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217Complete response (CR) rate at month 6Randomized · Quadruple-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: Sponsor decided to end the study | Drug: NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg · Other: Placebo Comparator | Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | 15 | 2024-05-22actual | — | 2025-02-13 |
| NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaNCT04136756Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 as a single agentNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NKTR-255, NKTR-255 Q21, Rituximab, Daratumumab | Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | 30 | 2023-04-24actual | — | 2023-06-15 |
| Study of NKTR 255 in Combination With Cetuximab in Solid TumorsNCT04616196results2025-06-08Incidence of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) of NKTR-255 in Combination With Cetuximab in R/R HNSCC or CRC for Phase 1b Dose EscalationOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: NKTR-255, Cetuximab | Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 25 | 2023-03-30actual | — | 2025-06-08 |
| A Phase I Study of LY3471851 in Healthy ParticipantsNCT05565729Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: LY3471851, Placebo, Levocetirizine | Healthy | 41 | 2023-02-23actual | — | 2023-11-18 |
| A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)NCT04433585results2024-04-23Percentage of Participants Who Achieved a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LY3471851, Placebo | Systemic Lupus Erythematosus | 291 | 2023-01-10actual | — | 2024-04-23 |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceNCT04410445results2023-04-21Recurrence-free Survival (RFS) by Blinded Independent Central Review (BICR) of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone.Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: (Sponsor decision) | Biological: Bempegaldesleukin, Nivolumab | Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin) | 765 | 2022-09-22actual | — | 2023-04-21 |
| A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)NCT04677179results2023-09-05Percentage of Participants Who Achieved Clinical Remission at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study terminated due to enrollment futility. | Drug: LY3471851, Placebo | Colitis, Ulcerative | 81 | 2022-08-09actual | — | 2023-09-05 |
| A Single-Dose Study of LY3471851 in Healthy ParticipantsNCT04998487Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: LY3471851 | Healthy | 71 | 2022-07-06actual | — | 2023-11-18 |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsNCT03138889results2023-03-09Number of Participants Experiencing Dose-Limiting Toxicities in Dose Optimization Cohort 1aNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: NKTR-214, Pembrolizumab, NKTR-214, NKTR-214, Cisplatin, Carboplatin, Nab paclitaxel, Paclitaxel, Pemetrexed, Atezolizumab | Non-Small Cell Lung Cancer | 162 | 2022-07-05actual | — | 2023-03-10 |
| A Study of LY3471851 in Participants With EczemaNCT04081350Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: LY3471851, Placebo | Dermatitis, Atopic | 48 | 2022-06-24actual | — | 2024-02-20 |
| REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesNCT03435640results2023-03-08Number of Participants Experiencing Dose-Limiting Toxicities (DLTS)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons. | Drug: NKTR-262, bempegaldesleukin, nivolumab | Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma | 64 | 2022-05-09actual | — | 2023-03-08 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsNCT02983045results2023-03-13Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation WindowNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer | 557 | 2022-04-28actual | — | 2023-03-13 |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)NCT04969861results2022-12-15Overall SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with the study IDMC, have decided to discontinue PROPEL-36. | Drug: Bempegaldesleukin, Pembrolizumab | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | 1 | 2022-04-22actual | — | 2023-01-12 |
| A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerNCT03785925results2023-03-28Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have Low Programmed Cell Death Ligand (PD-L1) ExpressionOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Bempegaldesleukin, Nivolumab | Urinary Bladder Neoplasm, Neoplasm Metastasis | 192 | 2022-02-09actual | — | 2023-03-28 |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)NCT03729245results2023-04-11Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCCRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision | Biological: bempegaldesleukin, nivolumab · Drug: sunitinib, cabozantinib | Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | 623 | 2022-01-07actual | — | 2023-04-11 |
| A Study of LY3471851 in Participants With PsoriasisNCT04119557Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: Placebo, LY3471851 | Psoriasis | 30 | 2021-07-21actual | — | 2024-02-20 |
| A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabNCT04955262Lesion uptake of 89Zr-Df-IAB22M2C (CD8 PET/CT tracer) before and after monotherapy treatment with mechanistically different immunotherapies, bempegaldesleukin (NKTR-214) and nivolumab as well as after combination treatment with NKTR-214 and nivolumab.Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Did not initiate due to business reasons. IND is inactive. | Biological: Bempegaldesleukin (NKTR-214), Nivolumab · Drug: ⁸⁹Zr-Df-IAB22M2C | Metastatic Melanoma | 0 | Jun 2021 | — | 2021-07-08 |
| A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19NCT04646044results2024-03-12AUC of Bempegaldesleukin [Pharmacokinetic Parameter].Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Bempegaldesleukin, Standard of Care · Other: Placebo | Covid-19, Coronavirus Disease 2019 | 30 | 2021-05-11actual | — | 2024-03-12 |
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineNCT02915744results2021-08-27Overall Survival (OS) of PatientsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel | Metastasis, Breast Cancer | 178 | Jul 2020actual | — | 2023-04-14 |
| A Study of LY3471851 in Healthy ParticipantsNCT04133116Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: LY3471851, Placebo | Healthy | 36 | 2020-03-06actual | — | 2023-11-18 |
| A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.NCT03802227results2021-05-27Brain Activity Measured Via fMRIRandomized · Triple-masked · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: NKTR-181, Oxycodone IR | Moderate to Severe Chronic Pain | 8 | 2019-12-17actual | — | 2021-07-08 |
| A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)NCT03556007Safety and Tolerability of LY3471851 - Number of Participants Experiencing Adverse EventsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: LY3471851, Placebo | Systemic Lupus Erythematosus | 48 | 2019-08-29actual | — | 2023-11-18 |
| A Study of NKTR-358 (LY3471851) in Healthy ParticipantsNCT04380324Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: LY3471851, Placebo | Healthy | 100 | 2019-01-20actual | — | 2023-11-18 |
| A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid TumorsNCT02869295results2021-07-29Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: NKTR-214 | Unspecified Adult Solid Tumor, Protocol Specific | 28 | 2018-10-31actual | — | 2021-07-29 |
| Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer PainNCT02367820results2020-10-08Number of Participants Reporting Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: NKTR-181 BID tablets | Low Back Pain, Chronic Pain | 638 | Dec 2017actual | — | 2021-06-22 |
| An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 StudiesNCT01457118results2021-07-07Length of Exposure to NKTR-102Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2, NKTR-102 50 mg/m2 | Malignant Solid Tumor | 27 | Aug 2017actual | — | 2021-07-12 |
| A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)NCT01991678Pharmacokinetics (PK) of NKTR-102 and its metabolitesNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: 145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | 25 | May 2017actual | — | 2017-10-06 |
| Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back PainNCT02362672results2020-09-16The Change in Weekly (ie, 7-day Average) Pain Score at the End of Double-blind, Randomized Treatment Period, Relative to the Weekly Score at the End of Titration (Double-blind Baseline)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: NKTR-181 BID tablets, Placebo to match NKTR-181 BID tablets | Low Back Pain, Chronic Pain | 1,189 | Dec 2016actual | — | 2020-09-16 |
| A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and SafetyNCT01976143QTcF interval valuesOpen-label · Treatment | Phase 1 | Completed | Drug: NKTR-102 | Advanced Cancer, Metastatic Solid Tumors | 33 | Jun 2016actual | — | 2016-12-22 |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102)NCT01492101results2021-06-01Kaplan-Meier Estimate of Overall Survival: Intention to Treat (ITT) PopulationRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: NKTR-102, Treatment of Physician's Choice (TPC) | Locally Recurrent Breast Cancer, Metastatic Breast Cancer | 852 | Apr 2016actual | — | 2021-06-01 |
| NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal CancerNCT00856375results2021-06-14Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT PopulationRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: NKTR-102, irinotecan | Colorectal Cancer | 83 | Jul 2014actual | — | 2021-07-12 |
| A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee PainNCT01619839results2021-08-02The Mean Change From Baseline Pain Score to Pain Score at the End of the Double-blind Randomized Treatment Period.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NKTR-181, Placebo | Osteoarthritis of the Knee | 296 | Aug 2013actual | — | 2021-08-02 |
| Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian CancerNCT00806156results2021-06-14Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST): Primary Efficacy PopulationRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: NKTR-102 q14d, NKTR-102 q21d | Tumor, Ovarian Cancer | 178 | Oct 2012actual | — | 2021-07-12 |
| Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast CancerNCT00802945results2018-07-09Objective Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: NKTR-102, NKTR-102 | Tumor, Breast Cancer | 70 | Oct 2011actual | — | 2018-07-09 |
| NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)NCT00598975results2021-06-14Number of Patients With Dose Limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab | Tumor, Colorectal Cancer | 18 | May 2009actual | — | 2021-07-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19